Literature DB >> 29987924

Applying an Electrophilicity-Based Strategy to Develop a Novel Nrf2 Activator Inspired from Dietary [6]-Shogaol.

Yu-Ting Du1, Ya-Long Zheng1, Yuan Ji1, Fang Dai1, Yong-Jing Hu1, Bo Zhou1.   

Abstract

Activation of nuclear factor erythroid-2-related factor 2 (Nrf2) is a crucial cellular defense mechanisms against oxidative stress and also an effective means to decrease the risk of oxidative stress-related diseases including cancer. Thus, identifying novel Nrf2 activators is highly anticipated. Inspired from [6]-shogaol (6S), an active component of ginger, herein we developed a novel potent Nrf2 activator, (1E,4E)-1-(4-hydroxy-3-methoxyphenyl)-7-methylocta-1,4,6-trien-3-one (SA) by an electrophilicity-based strategy. Compared with the parent 6S, SA bearing a short but entirely conjugated unsaturated ketone chain manifested the improved electrophilicity and cytoprotection (cell viability for the 10 μM 6S- and SA-treated group being 48.9 ± 5.3% and 76.1 ± 3.2%, respectively) against tert-butylhydroperoxide ( t-BHP)-induced cell death (cell viability for the t-BHP-stimulated group being 42.4 ± 0.4%) of HepG2. Mechanistic study uncovers that SA works as a potent Nrf2 activator by inducing Keap1 modification, inhibiting Nrf2 ubiquitylation and phosphorylating ERK in a Michael acceptor-dependent fashion. Taking 6S as an example, this works illustrates the feasibility and importance of applying an electrophilicity-based strategy to develop Nrf2 activators with dietary molecules as an inspiration due to their low toxicity and extraordinarily diverse chemical scaffolds.

Entities:  

Keywords:  Michael acceptor; Nrf2; [6]-shogaol; electrophilicity; oxidative stress

Mesh:

Substances:

Year:  2018        PMID: 29987924     DOI: 10.1021/acs.jafc.8b02442

Source DB:  PubMed          Journal:  J Agric Food Chem        ISSN: 0021-8561            Impact factor:   5.279


  1 in total

Review 1.  Benefits of Ginger and Its Constituent 6-Shogaol in Inhibiting Inflammatory Processes.

Authors:  Iris Bischoff-Kont; Robert Fürst
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.